Alzheimer's disease (AD), the most common cause of dementia in the elderly, is now the fourth major cause of death in the United States. AD is characterized and diagnosed by distinctive neuropathological alterations including extracellular deposits of the B-amyloid (AB)peptide. Epidemiological investigations have demonstrated that AD is a complex, age-related disorder with numerous genetic and environmental etiologies. One of the major difficulties in understanding the relationship between the various genetic, environmental and therapeutic factors that may modify the onset and progression of AD has been the lack of accurate and defined genetic models of the disease. Over the past decade numerous groups have generated transgenic mice using human AD gene fragments. These models, by definition, rely on certain assumptions regarding the fragment of the gene(s) to be expressed as well as the promoter utilized to drive expression of the transgene and are often maintained on ill-defined mixed genetic backgrounds all of which complicate their utility for studying factors that modify AD phenotypes. By contrast, we have focused on developing genomic-based mouse models of AD (""""""""genocopies""""""""), through the introduction of complete copies of human AD genes into the germline of mice and have recently established a genomic-based model in the four different mouse strains whose genomes have been sequenced. Importantly, our recent data demonstrates that genetic background in the mouse dramatically alters both the metabolism and deposition of the AB peptide in the brains of these models.
The specific aims of the current proposal are to utilize these unique mouse models to identify in vivo genetic modifiers of AB metabolism and deposition by: 1) Characterization of the age-related molecular, biochemical and neuropathological phenotypes of the four mouse strains. 2) Genetic mapping studies to identify candidate genes that regulate AB metabolism and AB deposition. 3) Candidate gene analysis through gene expression microarray analysis, transgenesis and analysis of the role of the candidate genes in human AD.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
5R01AG023012-05
Application #
7431680
Study Section
Neurodegeneration and Biology of Glia Study Section (NDBG)
Program Officer
Snyder, Stephen D
Project Start
2004-08-15
Project End
2009-07-31
Budget Start
2008-07-01
Budget End
2009-07-31
Support Year
5
Fiscal Year
2008
Total Cost
$261,646
Indirect Cost
Name
Cleveland Clinic Lerner
Department
Other Basic Sciences
Type
Schools of Medicine
DUNS #
135781701
City
Cleveland
State
OH
Country
United States
Zip Code
44195
Mlodzianoski, Michael J; Cheng-Hathaway, Paul J; Bemiller, Shane M et al. (2018) Active PSF shaping and adaptive optics enable volumetric localization microscopy through brain sections. Nat Methods 15:583-586
Bemiller, Shane M; Maphis, Nicole M; Formica, Shane V et al. (2018) Genetically enhancing the expression of chemokine domain of CX3CL1 fails to prevent tau pathology in mouse models of tauopathy. J Neuroinflammation 15:278
Maphis, Nicole M; Jiang, Shanya; Binder, Jessica et al. (2017) Whole Genome Expression Analysis in a Mouse Model of Tauopathy Identifies MECP2 as a Possible Regulator of Tau Pathology. Front Mol Neurosci 10:69
Bemiller, Shane M; McCray, Tyler J; Allan, Kevin et al. (2017) TREM2 deficiency exacerbates tau pathology through dysregulated kinase signaling in a mouse model of tauopathy. Mol Neurodegener 12:74
Maphis, Nicole; Jiang, Shanya; Xu, Guixiang et al. (2016) Selective suppression of the ? isoform of p38 MAPK rescues late-stage tau pathology. Alzheimers Res Ther 8:54
Andreasson, Katrin I; Bachstetter, Adam D; Colonna, Marco et al. (2016) Targeting innate immunity for neurodegenerative disorders of the central nervous system. J Neurochem 138:653-93
Komuro, Yutaro; Xu, Guixiang; Bhaskar, Kiran et al. (2015) Human tau expression reduces adult neurogenesis in a mouse model of tauopathy. Neurobiol Aging 36:2034-42
Savage, Julie C; Jay, Taylor; Goduni, Elanda et al. (2015) Nuclear receptors license phagocytosis by trem2+ myeloid cells in mouse models of Alzheimer's disease. J Neurosci 35:6532-43
Maphis, Nicole; Xu, Guixiang; Kokiko-Cochran, Olga N et al. (2015) Loss of tau rescues inflammation-mediated neurodegeneration. Front Neurosci 9:196
Jay, Taylor R; Miller, Crystal M; Cheng, Paul J et al. (2015) TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer's disease mouse models. J Exp Med 212:287-95

Showing the most recent 10 out of 29 publications